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IngBACKGROUND Although digoxin has long been used to treat atrial ﬁbrillation (AF) and heart failure (HF), its safety
remains controversial.
OBJECTIVES This study sought to describe digoxin use over time in patients with AF who were stratiﬁed by the
presence or absence of HF, to characterize the predictors of digoxin use and initiation, and to correlate digoxin use with
outcomes.
METHODS Longitudinal patterns of digoxin use and its association with a variety of outcomes were assessed in a
prospective outpatient registry conducted at 174 U.S. sites with enrollment from June 2010 to August 2011.
RESULTS Among 9,619 patients with AF and serial follow-up every 6 months for up to 3 years, 2,267 (23.6%) received
digoxin at study enrollment, 681 (7.1%) were initiated on digoxin during follow-up, and 6,671 (69.4%) were never
prescribed digoxin. After adjusting for other medications, heart rate was 72.9 beats/min among digoxin users and
71.5 beats/min among nonusers (p < 0.0001). Prevalent digoxin use at registry enrollment was not associated with
subsequent onset of symptoms, hospitalization, or mortality (in patients with HF, adjusted hazard ratio [HR] for death:
1.04; without HF, HR: 1.22). Incident digoxin use during follow-up was not associated with subsequent death in patients
with HF (propensity adjusted HR: 1.05), but was associated with subsequent death in those without HF (propensity
adjusted HR: 1.99).
CONCLUSIONS After adjustment for detailed clinical factors, digoxin use in registry patients with AF had a neutral
association with outcomes under most circumstances. Because of the multiple conﬂicting observational reports about
digoxin’s safety and possible concerns in speciﬁc clinical situations, a large pragmatic trial of digoxin therapy in AF is
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AND ACRONYMS
AF = atrial ﬁbrillation
CI = conﬁdence interval
eGFR = estimated glomerular
ﬁltration rate
EHRA = European Heart
Rhythm Association
HF = heart failure
HFrEF = heart failure with
reduced ejection fraction
HR = hazard ratio
HRQOL = health-related
quality of life
LVEF = left ventricular ejection
fraction
OR = odds ratio
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2692C ardiac glycosides, such as digoxin,have been used for decades to treatpatients with atrial ﬁbrillation (AF)
and those with heart failure (HF) to slow
atrioventricular nodal conduction and in-
crease cardiac inotropy (1). With the develop-
ment of alternative treatments for AF (2) and
HF (3), as well as concerns about digoxin’s
potential proarrhythmic properties and
long-term effects on cardiac remodeling (4),
prescribing digoxin has decreased and is no
longer recommended as ﬁrst-line therapy
for either disease (3,5). However, there
remain unmet needs for the treatment of
many subgroups of AF patients, including
those with HF, which has prompted calls
for renewed use of digoxin in certain clinical
situations (6).SEE PAGE 2699Effectiveness and safety data for digoxin are rela-
tively limited. The only large randomized trial of
digoxin, the DIG (Digitalis Investigation Group) trial,
showed no effect on mortality, but digoxin did reduce
hospitalization among patients with heart failure and
a reduced ejection fraction (HFrEF) (7). This trial only
enrolled patients in sinus rhythm, was conducted
between 1991 and 1993, and raised safety concerns at
higher serum concentrations and in certain sub-
groups, including women (8–10). A more recent
observational analysis of patients with incident
HFrEF under routine care found that digoxin use was
independently associated with higher mortality (11).
There are currently no large randomized trials of
digoxin in patients with AF. Two post-hoc non-
randomized analyses of data from the large AFFIRM
(Atrial Fibrillation Follow-up Investigation of Rhythm
Management) trial came to conﬂicting conclusions
(12,13). Post-hoc analysis of other AF trials have
shown higher mortality associated with digoxin use
(14), as have real-world data from a large incident AF
cohort from the Veterans Administration (15) and 2
large health maintenance organizations (16).
Due to limited and conﬂicting data, we set out
to describe digoxin use over time among a largelishing; and has received research grants from Medtronic and S
m Janssen Pharmaceuticals, Sanoﬁ, Genentech, Daiichi-Sankyo
for Boehringer Ingelheim, AstraZeneca, and Janssen Pharmaceu
arma, Boston Scientiﬁc, Gilead, Janssen Pharmaceuticals, ResMed
Rx, Johnson & Johnson, Medtronic, and Spectranetics. All other a
the contents of this paper to disclose.
is manuscript’s audio summary by JACC Editor-in-Chief Dr. Vale
received January 10, 2015; revised manuscript received March 3contemporary cohort of patients with AF who were
stratiﬁed by the presence or absence of HF, to char-
acterize predictors of digoxin use and initiation, and
to clarify the association of digoxin use with heart
rate, health-related quality of life (HRQOL) measures,
hospitalization, and survival.
METHODS
We used data from the ORBIT-AF (Outcomes Registry
for Better Informed Treatment of Atrial Fibrillation)
study to assess the use of digoxin and its association
with outcomes. Details of the ORBIT-AF study design
have been published previously (17). Brieﬂy, ORBIT-
AF was a U.S.-based, prospective outpatient registry
of AF conducted at 176 sites nationwide. The Duke
Clinical Research Institute was responsible for ORBIT-
AF site selection and study management. Eligible
patients were 18 years of age and older with electro-
cardiographically conﬁrmed AF. Enrolling providers
included cardiologists, electrophysiologists, and pri-
mary care providers. Site personnel entered infor-
mation on demographic characteristics, medical
history, cardiovascular risk factors, AF management
strategy, cardiac imaging, and provider characteris-
tics into a standardized, web-based collection form.
The presence or absence of HF and New York Heart
Association (NYHA) functional class were determined
at baseline by medical record review. Following initial
enrollment, longitudinal information was collected
during clinic visits at approximately 6-month intervals
for up to 36 months, and included information on
medication regimens, procedures, hospitalizations,
quality of life, and vital status. We excluded patients
whoweremissing information as towhether theywere
taking digoxin. Written informed consent was ob-
tained from all study participants. The Duke Institu-
tional Review Board approved the ORBIT-AF Registry;
all participating sites obtained approval from local
institutional review boards before entering patient
data.
Medication use was collected prospectively at
each study visit, including a ﬁeld speciﬁc for
digoxin. Dose and blood levels were not collected.
The follow-up visit date at which digoxin wast. Jude Medical. Dr. Peterson has received research
, Eli Lilly, and AstraZeneca; and has served as a
ticals. Dr. Piccini has received research grants from
, St. Jude Medical; and has served as a consultant for
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2693ﬁrst reported was deﬁned as the time period of
initiation.
The primary outcome of interest was all-cause
death. Additional outcomes of interest included heart
rate, symptoms,HRQOL, all-cause hospitalization, and
the composite of all-cause hospitalization and death.
Symptoms were measured using the European Heart
Rhythm Association (EHRA) score of AF-related
symptoms (18). HRQOL was assessed by the Atrial
Fibrillation Effect on Quality-of-Life questionnaire
in a subset of patients at baseline, and at 12 and
24 months (19).
STATISTICAL ANALYSIS. Characteristics between
patients were described as frequency and percent for
categorical variables and median (interquartile
ranges) for continuous variables. The characteristics
were compared using the chi-square test for cate-
gorical variables and the Wilcoxon rank sum test for
continuous variables. The cohort was divided into
those taking digoxin at study enrollment (prevalent
use), those initiated on digoxin during follow-up
(incident use), and those not on digoxin at any time
during the study. Characteristics among the groups
were compared using Pearson chi-square tests for
categorical variables and Wilcoxon rank sum tests for
continuous variables.
To examine factors associated with prevalent
digoxin use, a multivariable hierarchical logistic
regression model was constructed using backward
selection for the binary outcome of digoxin use at
baseline (see the covariates in Online Table 1 [54 pre-
speciﬁed clinical and demographic characteristics
and a random effect for the enrolling site] followed by
the inclusion criterion of p < 0.05 ﬁnal model cova-
riates in Online Table 2a). Prevalent digoxin users at
baseline were excluded from this model. Because
digoxin use was measured at 6-month visit intervals, a
second multivariable, discrete time Cox frailty model
was constructed for the time to the ﬁrst report of
digoxin initiation (ﬁnal model covariates in Online
Table 2b). Patients were censored from the risk set
when they were lost to follow-up (mainly due to stag-
gered entry into the cohort). A third discrete time Cox
frailty model was constructed for digoxin discontinu-
ation among prevalent digoxin users (ﬁnal model
covariates in Online Table 2c). Results were presented
as odds ratios (ORs) and/or hazard ratios (HRs) with
corresponding 95% conﬁdence intervals (CIs) and
p values.
Baseline heart rate was compared for baseline
digoxin use using a linear regression model that
accounted for other rate control medications (i.e.,
beta-blockers, verapamil, diltiazem, sotalol, and
amiodarone). The adjusted mean heart rate wasestimated by the model predicted heart rate, with and
without digoxin, with the adjustment variables set
equal to their population average.
Associations between prevalent digoxin use at
baseline and subsequent all-cause death, all-cause
hospitalization, cardiovascular hospitalization, and
onset of symptoms were assessed in unadjusted and
adjusted analysis. According to the pre-speciﬁed
analysis plan, primary analyses were stratiﬁed a pri-
ori by the presence or absence of HF. Time to ﬁrst
reported symptoms was measured at 6-month visit
intervals, and a discrete time Cox model was used for
this outcome only; otherwise, exact event dates were
used. The potential for clustering of patient outcomes
within a site was handled by adding a random effect
for site (multivariable Cox frailty model). Models
were adjusted for all covariates listed in Online
Table 3, which were determined to have: 1) partic-
ular clinical relevance, determined a priori; or 2) a
statistically signiﬁcant association with any of the
outcomes under evaluation, as previously identiﬁed
by backward selection with stay criteria of 0.05. The
same set of covariates was used for adjustment of all
outcomes. Adjusted associations for outcomes were
displayed as HRs (95% CI).
Associations between incident digoxin use in
follow-up and subsequent all-cause death, all-cause
hospitalization, and cardiovascular hospitalization
were assessed through propensity score matching
between patients initiated on digoxin at follow-up. It
was unusual to have subsequent follow-up in subjects
who initiated digoxin at the ﬁnal follow-up period
(30 to 36 months); therefore, digoxin initiation was
restricted to occur between 6 and 24 months. Anal-
yses were conducted separately for patients with and
without HF. Each case (incident digoxin use) was
matched to 3 control subjects (noninitiators) using
sequential stratiﬁcation matching (20), which identi-
ﬁed matches from the same point in follow-up at
which digoxin was initiated and used all available
covariate information up to that point (including HF
status). The criteria for matching was a single pro-
pensity score, obtained from a logistic regression
model for digoxin initiation. Matching was conducted
sequentially, starting at 6 months and moving for-
ward through follow-up. At each visit, patients who
initiated digoxin were matched to other subjects
who were still under follow-up at the same time, but
who had not yet started digoxin. The criteria for
identifying a match was “closeness” on a single pro-
pensity score value calculated at each visit. To be
considered a match, patients had to have a difference
in propensities no greater than a caliper of 20% of a
SD. Standardized differences were used to evaluate
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2694the success of propensity matching at achieving bal-
ance. Outcomes assessment began immediately after
the time period of initiation, and the model was ﬁt
using stratiﬁed Cox regression, stratiﬁed on the
matched pair (21).
Pre-deﬁned secondary analyses were performed
in patient subgroups with renal function (esti-
mated glomerular ﬁltration rate [eGFR] <60 and $60
ml/min/1.73 m2) and left ventricular ejection fraction
(LVEF) (<40% and $40%).
All candidate variables had <2% missing factors,
except for level of education (4%), serum creatinine
(7%), hematocrit (10%), LVEF (11%), and left atrial
diameter (14%). Missing data were handled with
single imputation. Imputed values were obtained by
the Markov chainMonte Carlomethod or by regression
methods (22).
For all models, continuous variables were evalu-
ated for nonlinearity with the outcome and when
nonlinear ﬁt with linear splines. All analyses were
performed using SAS software version 9.3 (SAS Insti-
tute, Cary, North Carolina).
RESULTS
PATIENT CHARACTERISTICS AND PATTERNS OF
DIGOXIN USE. Between June 2010 and August 2011,
10,132 patients were enrolled in ORBIT-AF from 176
sites; 490 patients (4.8%) were then excluded due to
lack of follow-up data, and 23 patients (0.2%) were
excluded due to a missing response for digoxin use at
baseline or follow-up. This resulted in a ﬁnal cohort
of 9,619 patients from 174 sites. Mean follow-up was
22 months (interquartile range: 17 to 25). Digoxin use
was reported in 2,267 patients (23.6%) at the time of
study enrollment, and an additional 681 patients
(7.1%) were initiated on digoxin during follow-up,
leaving 6,671 patients (69.4%) who were never on
digoxin. Of those on digoxin at baseline, 794 patients
(35.0%) discontinued digoxin during follow-up, and,
of these, 217 (27.3%) subsequently resumed digoxin.
Baseline characteristics of the overall study popu-
lation stratiﬁed by digoxin use are shown in Table 1.
HF was present in 3,161 patients (32.9%) of the cohort,
among whom prevalent digoxin use at baseline was
present in 1,091 patients (34.5%). Incident use in
follow-up was observed in another 268 patients
(8.5%). Beta-blockers were prescribed in 69.6% of
patients on digoxin compared with 62.4% of those
never on digoxin; nondihydropyridine calcium
channel blockers were prescribed in 18.6% of patients
on digoxin compared with 16.0% of patients who
never received digoxin. Antiarrhythmic medications
were prescribed in 17.6% of patients on digoxincompared with 32.6% of patients who never received
digoxin.
Factors independently associated with digoxin use
at baseline included the following: rate control
strategy and absence of previous ablation; permanent
AF; worse HF functional class and LVEF; sinus node
dysfunction; larger left atria; lower diastolic blood
pressure; better renal function; faster heart rate;
history of diabetes, hyperthyroidism, or chronic
obstructive pulmonary disease; and female sex (the
full model is presented in Online Table 2a). Multi-
variable predictors of the initiation of digoxin in
follow-up were relatively similar to those for baseline
use (the full model is shown in Online Table 2b).
Multivariable baseline predictors of discontinuation
during follow-up were the following: new-onset,
paroxysmal, or persistent AF; bradycardia or tachy-
cardia; no previous myocardial infarction; previous
use of an antiarrhythmic drug; lower eGFR; higher
EHRA score; and higher systolic blood pressure (the
full model is shown in Online Table 2c).
The overall mean heart rate at baseline was 71.9 
13 beats/min, with a higher unadjusted heart rate
(73.1  12.7 beats/min) among prevalent digoxin users
compared with those not on digoxin at baseline
(71.5  13.1 beats/min; p for comparison < 0.001).
After adjustment for other rate control medications,
the adjusted heart rate remained slightly higher
among digoxin users (72.9 beats/min) than nonusers
at baseline (71.5 beats/min; p < 0.0001).
QUALITY OF LIFE, SYMPTOMS, AND OUTCOMES. EHRA
symptom scores were not signiﬁcantly different
among prevalent or incident digoxin patients versus
patients not on digoxin (p ¼ 0.09 and p ¼ 0.58,
respectively) (Table 1). In the quality-of-life substudy,
unadjusted HRQOL was slightly lower in patients
who received digoxin than those who were never on
digoxin, both at baseline (Atrial Fibrillation Effect on
Quality-of-Life questionnaire overall score median
[interquartile range]: prevalent 78.7 [62.0 to 92.6];
incident 79.2 [64.8 to 88.9]; never 83.3 [68.5 to 93.5];
p ¼ 0.0002) and at 1 year (prevalent 80.6 [66.7 to
91.7]; incident 79.6 [64.8 to 95.4]; never 86.6 [73.1 to
95.4]; p ¼ 0.0001). The majority of prevalent digoxin
patients who had follow-up were without symptoms,
with an EHRA score of 0 in 51% to 53% of patients at
6, 12, 18, and 24 months. In multivariable analysis,
digoxin use had a neutral association with the fre-
quency of worsening AF symptoms in both patients
with HF (Central Illustration, panel A) and patients
without HF (Central Illustration, panel B).
Hospitalization for any cause occurred in 4,326
patients (45.0%), cardiovascular hospitalization in
2,485 patients (26.0%), and death in 865 patients
TABLE 1 Selected Baseline Characteristics of Patients by Digoxin Use
Overall
(N ¼ 9,619)
Prevalent Digoxin
(n ¼ 2,267)
Incident Digoxin
(n ¼ 681)
No Digoxin
(n ¼ 6,671)
p Value (Prevalent
vs. Never)
p Value (Incident
vs. Never)
Demographics
Age, yrs 75 (67–82) 76 (67–83) 76 (68–81) 75 (67–81) <0.0001 0.12
Female 4,088 (43) 1,009 (45) 299 (44) 2,780 (42) 0.018 0.26
Body mass index, kg/m2 29.1 (25.4–34.0) 27.9 (24.3–32.6) 29.0 (25.4–34.4) 29.5 (25.8–34.4) <0.0001 0.15
Heart rate, beats/min 70 (63–80) 72 (64–80) 72 (64–81) 70 (62–79) <0.0001 <0.0001
Systolic BP, mm Hg 126 (116–138) 124 (112–136) 124 (112–136) 126 (118–138) <0.0001 <0.001
Diastolic BP, mm Hg 72 (66–80) 70 (64–80) 70 (66–80) 72 (68–80) <0.0001 0.006
Medical history
Diabetes 2,837 (29) 822 (36) 215 (32) 1,800 (27) <0.0001 0.011
Hyperthyroidism 196 (2) 62 (3) 21 (3) 113 (2) 0.002 0.010
COPD 1,581 (16) 476 (21) 124 (18) 981 (15) <0.0001 0.015
Hyperlipidemia 6,961 (72) 1,647 (73) 470 (69) 4,844 (73) 0.98 0.045
Sick sinus syndrome 1,706 (18) 488 (22) 131 (19) 1,087 (16) <0.0001 0.049
No HF 6,458 (67) 1,176 (52) 413 (61) 4,869 (73)
NYHA functional class I HF 1,006 (10) 326 (14) 96 (14) 584 (9) <0.0001 <0.0001
NYHA functional class II HF 1,440 (15) 499 (22) 109 (16) 832 (12)
NYHA functional class III/IV HF 700 (7) 262 (12) 62 (9) 376 (6)
Previous MI 1,547 (16) 430 (19) 127 (19) 990 (15) <0.0001 0.008
Previous CABG 1,428 (15) 346 (15) 119 (17) 963 (14) 0.34 0.033
Studies
LVEF, #40% or moderate to
severely reduced
1,263 (13) 526 (23) 118 (17) 619 (9) <0.0001 <0.0001
Left atrium, moderate or
severe enlargement
3,799 (39) 1,077 (48) 306 (45) 2,416 (36) <0.0001 <0.0001
IVCD 1,062 (11) 281 (12) 65 (10) 716 (11) 0.001 0.040
RBBB 806 (8) 201 (9) 77 (11) 528 (8)
LBBB 376 (4) 103 (5) 27 (4) 246 (4)
eGFR, ml/min/1.73 m2 67 (53–82) 67 (54–83) 65 (51–81) 67 (53–82) 0.3853 0.1223
AF history
New-onset AF 429 (4) 64 (3) 35 (5) 330 (5) <0.0001 0.16
Paroxysmal AF 4,874 (51) 862 (38) 353 (52) 3,659 (55)
Persistent AF 1,610 (17) 461 (20) 100 (15) 1,049 (16)
Rhythm control strategy 3,043 (32) 416 (18) 199 (29) 2,428 (36) <0.0001 <0.001
Previous cardioversion 2,907 (30) 659 (29) 225 (33) 2,023 (30) 0.26 0.14
Previous antiarrhythmic drug 4,403 (46) 921 (41) 311 (46) 3,171 (48) <0.0001 0.35
Catheter ablation of AF 538 (6) 75 (3) 29 (4) 434 (7) <0.0001 0.021
AV node ablation 217 (2) 32 (1) 9 (1) 176 (3) 0.001 0.037
EHRA scores
No symptoms 3,676 (38) 856 (38) 247 (36) 2,573 (39) 0.09 0.58
Mild symptoms 4,332 (45) 1,021 (45) 323 (47) 2,988 (45)
Severe symptoms 1,398 (15) 353 (16) 93 (14) 952 (14)
EHRA score–disabling 172 (2) 29 (1) 13 (2) 130 (2)
Values are median (interquartile range) or n (%).
AF ¼ atrial ﬁbrillation; AV ¼ atrioventricular; BP ¼ blood pressure; CABG ¼ coronary artery bypass grafting; COPD ¼ chronic obstructive pulmonary disease; eGFR ¼
estimated glomerular ﬁltration rate; EHRA ¼ European Heart Rhythm Association; HF ¼ heart failure; IVCD ¼ interventricular conduction delay; LBBB ¼ left bundle branch
block; LVEF ¼ left ventricular ejection fraction; MI ¼ myocardial infarction; NYHA ¼ New York Heart Association; RBBB ¼ right bundle branch block.
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2695(9.0%). Prevalent use of digoxin at registry enroll-
ment among patients with and without HF was not
associated with all-cause hospitalization, cardiovas-
cular hospitalization, symptoms, or death (Central
Illustration, panels A and B). Among patients with
eGFR <60 ml/min/1.73 m2, digoxin use at enrollment
had a borderline association with subsequent death
(adjusted HR: 1.23; 95% CI: 1.00 to 1.51) and ﬁrstall-cause hospitalization (adjusted HR: 1.14; 95% CI:
1.01 to 1.28).
Incident use of digoxin during follow-up among
patients with and without HF after propensity
matching (Online Tables 4a and 4b) was not associ-
ated with all-cause hospitalization, cardiovascular
hospitalization, or symptoms (Central Illustration,
panels C and D). Incident digoxin use was not
CENTRAL ILLUSTRATION Association of Digoxin Use With Subsequent Outcomes
Allen, L.A. et al. J Am Coll Cardiol. 2015; 65(25):2691–8.
In this assessment of longitudinal patterns of digoxin use in patients with atrial ﬁbrillation (AF) with and without heart failure (HF), registry data were used to correlate
digoxin use with outcomes. Among patients receiving digoxin at study enrollment (prevalent), digoxin use was not associated with subsequent onset of symptoms,
hospitalization, or mortality in patients (A) with or (B) without HF. The same is true for (C) patients with HF who initiated digoxin during follow-up, although incident
digoxin use in patients (D) without HF was associated with subsequent death. CI ¼ conﬁdence interval; CV ¼ cardiovascular; HR ¼ hazard ratio.
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2696associated with subsequent death in those with HF
(adjusted HR: 1.05; 95% CI: 0.66 to 1.65) (Central
Illustration, panel C), but was associated with subse-
quent death in those without HF (adjusted HR: 1.99;
95% CI: 1.12 to 3.56) (Central Illustration, panel D).
Similarly, the association of incident digoxin use with
death was conﬁned to those with a LVEF >40%
(adjusted HR: 2.21; 95% CI: 1.32 to 3.71). Among
patients with eGFR <60 ml/min/1.73 m2, incident
digoxin use was not associated with death (adjusted
HR: 0.96; 95% CI: 0.51 to 1.82).
DISCUSSION
Within the context of multiple recent descriptions of
prescribing digoxin in a variety of patient popula-
tions, the ORBIT-AF registry provides a broadly
representative and clinically detailed look at the
patterns of digoxin use in patients with existing AF.
Despite the growing availability of alternative treat-
ments for AF patients with HF, the prevalent use of
digoxin in ORBIT-AF was 24% overall and even higher
among patients with HF, lower blood pressure, higher
heart rates, and female sex. Other contemporary data
showed similar rates of digoxin use: 23% use among
patients with incident AF (15) and 18% use among
patients with incident HFrEF (11). In follow-up out to3 years, 15% of ORBIT-AF patients either initiated or
discontinued the drug, suggesting that use was
dynamic. Digoxin was given with beta-blockers and
other rate and rhythm control agents in the majority
of patients.
DIGOXIN EFFECTIVENESS AND SAFETY. These data
add to the suboptimal body of evidence regarding the
effectiveness and safety of digoxin in AF patients with
and without HF. All positive cardiac inotropes that
act through calcium handling and sensitization—with
the notable exception of digoxin—have been shown
in controlled trials to promote left ventricular
remodeling and adverse events (23–26). The excep-
tion, the DIG trial, demonstrated equal survival in HF
patients randomized to digoxin versus placebo (7).
However, its conduct in the early 1990s, which pre-
dates most modern therapies for HFrEF, and its
exclusion of patients with AF, leave open many
questions. Since DIG, no high-quality, large, random-
ized trials of digoxin have been performed. Mean-
while, a variety of post hoc analyses of trial data have
found digoxin to be neutral to harmful in certain
subgroups. In SPORTIF III and V (Stroke Prevention
Using an Oral Thrombin Inhibitor in Atrial Fibrillation)
studies, digitalis use was 53%, and users had a
higher mortality than nonusers (14). The AFFIRM
study analysis, which incorporated time-dependent
J A C C V O L . 6 5 , N O . 2 5 , 2 0 1 5 Allen et al.
J U N E 3 0 , 2 0 1 5 : 2 6 9 1 – 8 Digoxin in Atrial Fibrillation: The ORBIT-AF Study
2697assessment of digoxin use, found an association be-
tween incident digoxin use and mortality (12,13).
Observational data from real-world practice have
generally come to similar conclusions. In a large
study of 2,891 Kaiser patients with newly diagnosed
HFrEF, of whom 22.9% had AF, incident digoxin use
was associated with higher mortality (HR: 1.72; 95%
CI: 1.25 to 2.36), but there was no signiﬁcant differ-
ence in the risk of HF hospitalization (HR: 1.05;
95% CI: 0.82 to 1.34) (11). The ATRIA-CVRN (Anti-
coagulation and Risk factors in Atrial Fibrillation-
Cardiovascular Research Network) study, which
was a propensity score matching analysis of 14,787
Kaiser patients with incident AF and without HF,
found that incident digoxin use was independently
associated with a higher risk of death (HR: 1.71; 95%
CI: 1.52 to 1.93) and a higher risk of hospitalization
(HR: 1.63; 95% CI: 1.56 to 1.71) (16). Recently, the
TREAT-AF (Retrospective Evaluation and Assessment
of Therapies in Atrial Fibrillation) study in 122,465
veterans with new-onset AF showed higher mortality
in those treated with digoxin (multivariable HR: 1.26;
95% CI: 1.23 to 1.29; and propensity matching HR:
1.21; 95% CI: 1.17 to 1.25) (15).
STUDY ADVANTAGES AND LIMITATIONS. The ORBIT-AF
registry has advantages over these other studies.
Unlike trial cohorts with narrow eligibility criteria
and mandated systematic follow-up, ORBIT-AF
captured a wide range of patients in routine care.
Unlike the Kaiser and TREAT-AF studies, which
relied on administrative coding for diagnoses and did
not study LVEF and functional status measures, the
prospective and rigorous clinical data captured in
ORBIT-AF were more likely to limit misclassiﬁcation
and accurately measure potential confounders. This
might be why the adjustment process in ORBIT-AF
showed greater reduction in the unadjusted to
adjusted HRs for digoxin in most of the analyses
performed.
Obviously, unaccounted for treatment selection
biases are likely to affect observational associations.
The contradictory ﬁndings from different statistical
analyses of the same AFFIRM database highlight this
potential (12,13). Although extensive covariates were
collected and modeled in this detailed prospective
ORBIT-AF registry, including LVEF, NYHA functional
class, vital signs, laboratory values, and concomitant
medications, unmeasured reasons for starting dig-
oxin might have at least partially confounded the
association observed between digoxin and out-
comes. Digoxin use is often dictated by hypotension,
intolerance to more typical agents (e.g., beta-
blockers), and worsening left ventricular dysfunc-
tion, all of which indicate worse disease. Digoxin isprescribed for AF largely for its ability to slow
atrioventricular nodal conduction; yet, even after
adjustment, digoxin was associated with higher
heart rates, suggesting residual unmeasured differ-
ences or issues with medication adherence that were
not measured.
Propensity matching, multivariable adjustment,
and stratiﬁed analysis all help to reduce such con-
founding, but these methods do not completely
address disease severity or many other facets of car-
diac health. Ultimately, higher quality data from ran-
domized trial designs that can remove treatment
selection biases are necessary to deﬁnitively assess
the effectiveness and safety of digoxin. Although
another large randomized trial of digoxin like the DIG
study is unlikely to be funded, evolving pragmatic
clinical trial designs offer opportunities in the near
future to test such a question through randomiza-
tion of real-world practices (27). Because there are
33 million individuals with AF across the globe,
determining whether or not digoxin is safe and
effective should be a key priority in future clinical
investigations.
Other limitations should be considered. ORBIT-AF
participating sites were selected to be representative
of the national AF population, but were not a true
cross section, such that results might not be gener-
alizable to all patients with AF; they also purposely
did not represent patients outside the United States.
Dose, serum digoxin concentration, and exact timing
of and reasons for digoxin initiation or discontinua-
tion were not collected.
CONCLUSIONS
Digoxin use remains common in the contemporary
treatment of AF. Overall, after statistical adjustment
for detailed clinical factors, digoxin had a neutral
association with a wide range of outcomes. Because
of ongoing questions about the safety of this com-
monly used medication, high-quality data derived
from a pragmatic clinical trial of real-world contem-
porary digoxin use is greatly needed.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Previous
studies have suggested that digoxin use might be asso-
ciated with adverse events in patients with AF; however,
after adjustment for patient characteristics in a contem-
porary cohort, there were no signiﬁcant interactions
across a range of outcomes.
TRANSLATIONAL OUTLOOK: Mixed results regarding
the safety of digoxin across multiple observational ana-
lyses call for higher quality evidence derived from prag-
matic clinical trials of digoxin in patients with AF.
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